Obesity Drug Pipeline Timeline 2026

What CagriSema Catalysts Are Expected in 2026?

CagriSema (cagrilintide + semaglutide) is the closest obesity drug to an FDA decision in 2026. Novo Nordisk filed the NDA in December 2025, placing the expected PDUFA date around October 2026. This is the single highest-impact regulatory catalyst of the year. For the current status of every pending submission, see our obesity drug approval tracker for 2026.

The filing is supported by the REDEFINE clinical program. The pivotal REDEFINE 1 trial showed 22.7% mean weight loss at 68 weeks, significantly exceeding the semaglutide-alone arm. CagriSema combines GLP-1 receptor agonism (semaglutide) with amylin receptor agonism (cagrilintide) in a single injection.

Beyond the FDA decision, the REDEFINE 6 trial (adolescent population, ages 12–17) is expected to read out in 2026. Positive adolescent data would expand the potential prescribing label significantly. Novo Nordisk has also disclosed plans for cardiovascular outcomes data from the REDEFINE program, though the timeline for those results extends beyond 2026.

What Retatrutide Data Is Coming in 2026?

Retatrutide is Eli Lilly’s triple agonist (GLP-1, GIP, and glucagon receptor agonist) and the most potent weight-loss drug in Phase 3 development. The TRIUMPH-4 trial reported topline results in August 2025 showing 28.7% mean body weight reduction at 68 weeks — the highest figure ever reported in a Phase 3 obesity trial. For a mechanistic deep dive, see our explainer on the triple agonist GIP, GLP-1, and glucagon pathway.

Seven additional TRIUMPH Phase 3 readouts are expected through 2026, making retatrutide the most data-rich pipeline asset this year:

TRIUMPH-1 (type 2 diabetes) — efficacy and safety in T2D patients. TRIUMPH-2 (weight maintenance) — whether weight loss is sustained after stepping down from the treatment dose. TRIUMPH-3 (obstructive sleep apnea) — an expanding-indications play following Zepbound’s OSA approval. TRIUMPH-5 (MASH/liver) — addressing metabolic liver disease. TRIUMPH-6 (HFpEF) — heart failure with preserved ejection fraction. TRIUMPH-7 (knee osteoarthritis) — a novel weight-related joint disease indication.

Eli Lilly has not confirmed an NDA filing date, but the breadth of the TRIUMPH program suggests a filing in late 2026 or early 2027. If filed in late 2026, an FDA decision would come no earlier than mid-to-late 2027. See our retatrutide vs tirzepatide vs CagriSema comparison for how these three leading candidates stack up.

When Will Orforglipron Phase 3 Results Be Complete?

Orforglipron is Eli Lilly’s oral non-peptide GLP-1 receptor agonist. The first Phase 3 readout — ATTAIN-1 — was positive, showing 12.4% mean weight loss at 72 weeks with the 36 mg dose (August 2025).

Three additional ATTAIN trials are expected to report in 2026: ATTAIN-2 (type 2 diabetes), ATTAIN-3, and ATTAIN-4. Completion of these trials would give Lilly a full regulatory data package for an NDA filing in obesity and potentially T2D.

Orforglipron’s competitive case rests on convenience: it is a once-daily pill with no food or water dosing restrictions, unlike the Wegovy pill which requires fasting conditions. However, the Wegovy pill has already reached market with stronger weight-loss data (16.6% in OASIS 4), so orforglipron will need to differentiate on practical dosing advantages.

An NDA filing is possible in late 2026 if the remaining ATTAIN readouts are positive and complete on schedule. That would put a potential FDA decision in 2027. For context on how all these pipeline agents compare, see our best research peptides guide for 2026.

Where Does Survodutide Stand in 2026?

Survodutide (Boehringer Ingelheim / Zealand Pharma) is a dual GLP-1/glucagon receptor agonist in the Phase 3 SYNCHRONIZE program. The program includes four trials: SYNCHRONIZE-1 (obesity), SYNCHRONIZE-2 (T2D), SYNCHRONIZE-3 (MASH), and SYNCHRONIZE-4.

No Phase 3 efficacy results have been reported yet. The Phase 2 data showed approximately 19% weight loss, which placed survodutide among the higher-efficacy investigational agents. The key question for 2026 is whether the SYNCHRONIZE program produces initial Phase 3 readouts by year-end or pushes into 2027.

Survodutide’s dual-agonist mechanism (GLP-1 + glucagon) differs from retatrutide’s triple-agonist approach and from CagriSema’s GLP-1/amylin combination, making it a structurally distinct competitive entry. Phase 2 data also showed liver-fat reduction, positioning it as a potential MASH therapy alongside its obesity indication. For help evaluating these candidates, see our analysis of the best obesity drug in 2026.

What Other Obesity Drugs Have 2026 Milestones?

Wegovy pill (oral semaglutide 25 mg). FDA approved in late 2025, the Wegovy pill is the first oral GLP-1 drug indicated for obesity, building on the Rybelsus oral semaglutide platform originally approved for diabetes. Commercial launch is ramping through early-to-mid 2026. Real-world uptake data will be a key milestone. OASIS 4 showed 16.6% mean weight loss.

Amycretin / Zenagamtide (Novo Nordisk). This unimolecular GLP-1/amylin agonist is in Phase 2. Results are expected in 2026 and will determine whether Novo Nordisk advances amycretin into Phase 3. Early Phase 1 data showed rapid weight loss over short treatment periods, generating significant anticipation.

VK2735 (Viking Therapeutics). The subcutaneous formulation is in Phase 3 (VANQUISH trial, enrolling). The oral formulation showed 12.2% weight loss at just 13 weeks in Phase 2 (VENTURE-Oral), the fastest rate of any oral agent in development. Oral Phase 3 is expected to start in 2026–2027.

Petrelintide (Roche / Zealand Pharma). This amylin analog reported 10.7% weight loss at 42 weeks in the Phase 2 ZUPREME-1 trial. Roche is evaluating whether to advance to Phase 3. A decision is expected in 2026.

Mazdutide (Innovent / Eli Lilly China). A dual GLP-1/glucagon agonist in the GLORY Phase 3 program in China. Results from the Chinese trials could come in 2026, though the regulatory pathway is distinct from the US/EU process.